47 completed, 4 active not recruiting, 4 unknown, 3 withdrawn. 62 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 62 | Completed 47, Active not recruiting 4, Unknown 4, Withdrawn 3, Not yet recruiting 2, Recruiting 1, Terminated 1 |
| Phase 2 | 8 | Completed 7, Unknown 1 |
Follow Hypertriglyceridemia: new trials by email Literature Review of Hypertriglyceridemia trials Research Report on Hypertriglyceridemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia DR10624 Injection, Matching Placebo for DR10624 - Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia | Phase 3 | Not yet recruiting | Zhejiang Doer Biologics Co., Ltd. | 480 | 2026-08-17 | 2026-07-10 |
| A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia DR10624 Subcutaneous Injection, Icosapent Ethyl Oral Capsule, Matching Placebo Subcutaneous Injection - Severe Hypertriglyceridemia | Phase 3 | Not yet recruiting | Zhejiang Doer Biologics Co., Ltd. | 378 | 2026-08-01 | 2026-07-06 |
| A Study of SHR-1918 In Participants With Hypertriglyceridemia SHR-1918/ SHR-1918 placebo - Hypertriglyceridemia | Phase 3 | Active not recruiting | Beijing Suncadia Pharmaceuticals Co., Ltd | 367 | 2026-03-31 | 2026-10-20 |
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis Plozasiran, Placebo - Severe Hypertriglyceridemia | Phase 3 | Recruiting | Arrowhead Pharmaceuticals | 288 | 2025-04-24 | 2026-09-21 |
| Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia Plozasiran Injection - Hypertriglyceridemia | Phase 3 | Active not recruiting | Arrowhead Pharmaceuticals | 710 | 2025-04-09 | 2026-10-01 |
| A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) mibavademab - Generalized Lipodystrophy | Phase 3 | Completed | Regeneron Pharmaceuticals | 9 | 2024-12-16 | 2026-07-29 |
| Study of Plozasiran in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 311 | 2024-07-23 | 2026-10-09 |
| Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Plozasiran Injection, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 446 | 2024-07-22 | 2026-10-08 |
| Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia Plozasiran Injection, Placebo - Hypertriglyceridemia | Phase 3 | Completed | Arrowhead Pharmaceuticals | 1456 | 2024-05-21 | 2026-09-25 |
| Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal Women Phytoestrogen, Diet control & life style modification - Dyslipidemias, Hypertriglyceridemia | Phase 2 / Phase 3 | Unknown | Dhurakij Pundit University | 10 | 2024-03-02 | 2024-05-24 |
| To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia Pegozafermin, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | 89bio, Inc. | 369 | 2023-06-15 | 2026-07-07 |
| CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) Olezarsen - Severe Hypertriglyceridemia | Phase 3 | Active not recruiting | Ionis Pharmaceuticals, Inc. | 885 | 2022-12-13 | 2025-12-01 |
| A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia Olezarsen, Placebo - Hypertriglyceridemia, Cardiovascular Diseases | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 1478 | 2022-11-21 | 2026-02-10 |
| A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 446 | 2022-08-31 | 2025-10-22 |
| Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP. Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose, Atorvastatin (Lipitor ®) - Dyslipidemia Associated With Type II Diabetes Mellitus | Phase 3 | Unknown | Laboratorios Silanes S.A. de C.V. | 78 | 2022-02-15 | 2022-03-02 |
| A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia Olezarsen, Placebo - Severe Hypertriglyceridemia | Phase 3 | Completed | Ionis Pharmaceuticals, Inc. | 617 | 2021-10-25 | 2026-02-10 |
| Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL Placebo, MAT9001 (omega-3 pentaenoic acid) - Severe Hypertriglyceridemia | Phase 3 | Withdrawn | Matinas Biopharma, Inc | 2021-06-01 | 2021-09-16 | |
| Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage SHR-1209, SHR-1209 Placebo - Primary Hypercholesterolemia, Mixed Hyperlipemia | Phase 3 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 709 | 2021-04-23 | 2023-05-19 |
| Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment Cipros 10 association, Crestor 10 mg - Hypertriglyceridemia, Dyslipidemia | Phase 3 | Completed | EMS | 146 | 2021-01-29 | 2025-12-08 |
| Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia Placebo, Ethyl Icosapentate - Hypertriglyceridemia | Phase 3 | Completed | Mochida Pharmaceutical Company, Ltd. | 316 | 2020-05-09 | 2024-07-15 |
Showing 20 of 62. Sign in to see all of them.
Dyslipidemias (15) · Hyperlipidemias (14) · Hypercholesterolemia (6) · Cardiovascular Diseases (3) · Diabetes Mellitus (3) · Diabetes Mellitus, Type 2 (3) · Hyperlipoproteinemia Type II (3) · Insulin Resistance (3) · Metabolic Diseases (3) · Obesity (3) · Hypertension (2) · Metabolic Syndrome (2) · Acute Coronary Syndrome (1) · Angina Pectoris (1)
Nutritional and Metabolic Diseases (62) · Lipid Metabolism Disorders (61) · Metabolic Diseases (59) · Hyperlipidemias (48) · Dyslipidemias (47) · Glucose Metabolism Disorders (8) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Endocrine System Diseases (6) · Genetic Diseases, Inborn (6) · Lipid Metabolism, Inborn Errors (6) · Metabolism, Inborn Errors (6) · Hyperinsulinism (5) · Hyperlipoproteinemias (5)
eicosapentaenoic acid ethyl ester (8) · Omacor (7) · plozasiran (5) · Atorvastatin (4) · Fenofibrate (4) · olezarsen (4) · Corn Oil (3) · Olive Oil (3) · Simvastatin (3) · eicosapentaenoic acid ethanolamide (3) · Eicosapentaenoic Acid (2) · Ezetimibe (2) · K-877 compound (2) · TAK-085 (2) · Ezetimibe, Simvastatin Drug Combination (1)
Arrowhead Pharmaceuticals (5) · AstraZeneca (5) · Ionis Pharmaceuticals, Inc. (5) · Amarin Pharma Inc. (3) · GlaxoSmithKline (3) · Mochida Pharmaceutical Company, Ltd. (3) · Organon and Co (3) · Grace Therapeutics Inc. (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · Kowa Research Institute, Inc. (2) · Takeda (2) · Zhejiang Doer Biologics Co., Ltd. (2) · 89bio, Inc. (1) · Abbott (1) · Babu Balagopal (1)
United States (30) · Canada (17) · Hungary (14) · Czechia (13) · Bulgaria (12) · Poland (12) · France (10) · Spain (10) · Germany (9) · Italy (9) · Netherlands (9) · Slovakia (9) · Argentina (8) · China (8) · United Kingdom (8)
Associate Professor, Clinical Cell Biology and Medicine (2) · Dariush Mozaffarian, MD, DrPH (2) · Kevin C Maki, PhD (2) · Michael H Davidson, MD, FACC (2) · Takuya Mori (2) · Angel Brea, MD (1) · Chuen-Den Tseng, M.D., PhD. (1) · Deepak L. Bhatt, MD, MPH (1) · Francisco G Padilla Padilla, M.D (1)
PMID 22087637, PMID 23325450, PMID 25893544, PMID 27206952, PMID 27418543, PMID 27596132, PMID 27939227, PMID 34989797, PMID 40064331, PMID 41211918, PMID 20451686, PMID 20524719, PMID 21683321, PMID 22108152, PMID 22819432, PMID 23312052, PMID 23835245, PMID 23992935, PMID 23998969, PMID 24528690, PMID 25084280, PMID 26044516, PMID 26073397, PMID 26328624, PMID 28324110, PMID 29583081, PMID 30415628, PMID 30788718, PMID 30898607, PMID 31277790, PMID 31306043, PMID 31439224, PMID 31707829, PMID 33010162, PMID 33148016, PMID 33798466, PMID 34620410, PMID 34706555, PMID 34710343, PMID 35027114, PMID 35261279, PMID 35377160, PMID 35483753, PMID 35762321, PMID 36802845, PMID 37164837, PMID 38035037, PMID 38156550, PMID 39968782, PMID 40081744
2023 (4), 2014 (1)